Polimorfismos de genes com atividade antioxidante e desintoxicante na predisposição para o Cancro Colo-retal by Jegundo,Patrícia Alexandra Sousa
 Universidade de Aveiro 
2015  
Departamento de Biologia 
Patrícia Alexandra 
Sousa Jegundo 
 
Polimorfismos de genes com atividade antioxidante 
e desintoxicante na predisposição para o Cancro 
Colo-retal 
 
Antioxidant and detoxify genes polymorphisms in 
colorectal cancer predisposition  
 
 
   
 

  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DECLARAÇÃO 
 
 
 
Declaro que este relatório é integralmente da minha autoria, estando devidamente 
referenciadas as fontes e obras consultadas, bem como identificadas de modo claro as 
citações dessas obras. Não contém, por isso, qualquer tipo de plágio quer de textos 
publicados, qualquer que seja o meio dessa publicação, incluindo meios eletrónicos, quer de 
trabalhos académicos. 

  
Universidade de Aveiro 
2015 
Departamento de Biologia 
Patrícia Alexandra 
Sousa Jegundo 
 
 
Polimorfismos de genes com atividade antioxidante 
e desintoxicante na predisposição para o Cancro 
Colo-retal 
 
Antioxidant and detoxify genes polymorphisms in 
colorectal cancer predisposition  
  
 
Dissertação apresentada à Universidade de Aveiro para cumprimento dos 
requisitos necessários à obtenção do grau de Mestre em Biologia Molecular e 
Celular, realizada sob a orientação científica da Professora Doutora Lina 
Carvalho, Professora Associada com Agregação do Instituto de Anatomia 
Patológica da Faculdade de Medicina da Universidade de Coimbra e da Mestre 
Sandra Balseiro, Professora Assistente da Escola Superior e Saúde Dr. Lopes 
Dias, Instituto Politécnico Castelo Branco e da Professora Doutora Maria de 
Lourdes Pereira, Professora Associada com Agregação do Departamento de 
Biologia da Universidade de Aveiro. 
 
 
 
 
 
 
 
 
 
 
 
 
  
 Este trabalho contou com a colaboração do Instituto de Anatomia e Patologia 
Molecular da Faculdade de Medicina da Universidade de Coimbra e foi 
financiado pelos projetos da CIMAGO (projeto nº19/2009) e do GAI (projeto 
LCarvalho.GAI2015) da FMUC.  
 
 
 
 

  
 
 
  
  
 Dedico este trabalho aos profissionais de saúde, pacientes e famílias que se 
deparam com a luta contra o cancro no seu dia-a-dia, bem como, aos que de 
algum modo deram o seu contributo para esta batalha. 
 
 “You may have to fight a battle more than once to win it.”  
                                                                       Margaret Thatcher 
 
 

   
 
  
 
O júri   
Presidente Prof. Doutor António Carlos Matias Correia,  
Professor Catedrático, Departamento de Biologia, Universidade de Aveiro 
  
 
 Prof. Doutora Lina Carvalho 
Professora Associada com Agregação, Faculdade de Medicina, Universidade 
de Coimbra 
  
Prof. Doutor Fernando de Jesus Regateiro 
Professor Catedrático, Faculdade de Medicina, Universidade de Coimbra 
  
  
  
  
 
  
  
 
  
  
 
  
 
 
 

  
 
 
 
Agradecimentos 
 
Em primeiro lugar agradeço às minhas orientadoras. À Professora Doutora 
Lina Carvalho pela oportunidade que me deu para desenvolver a minha tese 
no serviço de Anatomia Patológica da FMUC, pela sua disponibilidade e 
orientação científica. À Mestre Sandra Balseiro também pela oportunidade e 
disponibilidade, bem como, pela transmissão do seu conhecimento, por todo o 
ensinamento, paciência e ajuda no contorno dos obstáculos, pelo apoio e pela 
amizade durante todos estes anos que me leccionou e orientou. E à minha co-
orientadora Professora Doutora Maria de Lourdes Pereira pela sua orientação 
interna na Universidade de Aveiro.  
 
Agradeço também aos meus colegas de trabalho Raquel Pandeirada, Sofia 
Fernandes, Tifanny e José Pedro Mendes pela cooperação dentro e fora do 
laboratório, pelo bom ambiente partilhado e pelas suas amizades.  
 
Não menos importante, agradeço à equipa do serviço do IAP-FMUC, 
nomeadamente, à Maria Silva, à Maria João e à Natália pela disponibilidade 
que sempre demonstraram e pelo bom ambiente que proporcionaram.  
 
Agradeço ainda à Doutora Adriana Brito pela flexibilidade de trabalho que me 
deu, permitindo conciliar trabalho e estudos. 
 
Por fim e em especial, agradeço à minha família, namorado e amigos pelo 
incentivo, pelo apoio incondicional, pela motivação e por acreditarem sempre 
nas minhas capacidades e no meu trabalho, nos bons e maus momentos. 
 
Cada um da sua maneira contribuiu para a realização de mais este meu 
projeto, por isso um grande bem-haja a todos. 
 
 
 

   
 
 
 
 
 
 
 
 
 
 
Palavras-chave 
 
Adenocarcinamo colo-retal esporádico; Superóxido Dismutases; Glutationas S-
Transferases; Polimorfismos comuns; PCR. 
 
Resumo 
 
 
O cancro colo-retal (CCR) resulta de um conjunto gradual de alterações 
histológicas e genéticas, que se traduz numa proliferação celular 
descontrolada. Embora existam causas genéticas para a origem deste 
carcinoma, a maioria dos autores assume causas multifactoriais para a génese 
do CCR. Das causas não genéticas, a baixa atividade física, uma dieta rica em 
gorduras e pobre em fibras, bem como, os hábitos tabágicos parecem ter um 
papel preponderante no desenvolvimento desta patologia. Do mesmo modo, 
tem vindo a ser descrito que diferentes níveis de stresse oxidativo podem 
influenciar o desenvolvimento deste tipo de cancro. Desta forma, a 
manutenção celular do estado oxidação-redução parece ser crucial para a 
conservação da função dos tecidos e prevenção da carcinogénese. Variações 
genotípicas nos genes envolvidos neste processo, tais como, MNSOD, SOD3, 
GSTP1, GSTT1 e GSTM1, podem ser importantes biomarcadores para o CCR.  
 
Neste trabalho pretendeu-se determinar a distribuição da frequência dos 
polimorfismos mais comuns dos genes envolvidos na regulação do stresse 
oxidativo (MNSOD, SOD3, GSTP1, GSTT1 e GSTM1) em indivíduos com 
adenocarcinoma colo-retal esporádico (ACE) e em controlos saudáveis, 
avaliando assim a sua possível correlação com o risco para o desenvolvimento 
do ACE. A análise dos polimorfismos dos genes com atividade desintoxicante 
e desintoxicante (MNSOD T175C, SOD3 R213G, GSTP1 A105G, GSTP1 
C114T, GSTT1del e GSTM1del) foi feita através da técnica de PCR-SSP. 
 
Neste estudo encontrámos uma prevalência dos genes mutados nos pacientes 
com ACE, comparativamente com o grupo controlo: MNSOD 175CC (55% vs 
2%; p<0,0001; OR: 58,5; CI 13,3 a 256,7), SOD3 213GG (31% vs 2%; 
p<0,0001; OR: 21,89; CI 4,93 a 97,29), GSTP1 105GG (46% vs 12%; 
p<0,0001; OR: 6,14; CI 2,85 a 13,26), GSTP1 114TT 38%  vs 0%; p<0,0001; 
OR: Infinito) e GSTT1 del (75% vs 28%; p<0,0001; OR: 7,71; CI 3,83 a 15,56). 
Além disto, observámos também que os genótipos mutados GSTP1 114TT 
(52% vs 27%; p=0,003; OR: 2,88; CI: 1,41 a 5,89) e GSTT1 del (87% vs 65%; 
p=0.003; OR: 3.66; CI 1.51 a 8.84) estavam associados com o colon. 
 
Deste modo, os nossos resultados sugerem uma associação positiva entre os 
polimorfismos dos genes estudados e a prevalência do ACE. Assim sendo, a 
desregulação dos genes MNSOD, SOD3, GSTP1, GSTT1 e GSTM1 pode ser 
associada com um aumento de ROS no tecido do colon-retal. Além disto, o 
stresse oxidativo nas células do tecido colon-retal pode também induzir uma 
desregulação da via da p53. Este estudo evidência assim que os 
polimorfismos MNSOD 175C, SOD3 213G, GSTP1 105G, GSTP1 114T e 
GSTT1 del poderão estar envolvidos no risco para o ACE, permitindo clarificar 
esta patologia multifactorial.  
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Abstract 
 
Colorectal cancer (CRC) results from histologic and gene alterations can lead 
to a massive cellular proliferation. Most of the authors assume multifactorial 
causes to CRC genesis. Low physical activity, a fat diet poor in fibers and 
smoking habits seems to have an important role in CRC. However, there are 
also genetic causes associated with CRC risk. It has been described that 
oxidative stress levels could influence CRC development. Thus, cellular 
balance reactive species and defense enzymes involved in oxidative stress are 
crucial to maintain a good tissue function and avoid neoplasic process. 
Therefore, genome variations on these defense enzymes, such as MNSOD, 
SOD3, GSTP1, GSTT1 and GSTM1, could be important biomarkers to 
colorectal adenocarcinomas. 
 
We intend to determine frequencies distribution of most common 
polymorphisms involved on oxidative stress regulation (MNSOD, SOD3, 
GSTP1, GSTT1 and GSTM1) in patients with sporadic colorectal 
adenocarcinoma (SCA) and in healthy controls, evaluation their possible 
correlation with SCA risk. Samples common polymorphisms of antioxidant and 
detoxify genes (MNSOD T175C, SOD3 R213G, GSTP1 A105G, GSTP1 
C114T, GSTT1del and GSTM1del) analysis was done by PCR-SSP 
techniques. 
 
In this study we found a higher prevalence of MNSOD 175CC (55% vs 2%; 
p<0.0001; OR: 58.5; CI 13.3 to 256.7), SOD3 213GG (31% vs 2%; p<0.0001; 
OR: 21.89; CI 4.93 to 97.29), GSTP1 105GG (46% vs 12%; p<0.0001; OR: 
6.14; CI 2.85 to 13.26), GSTP1 114TT (38%  vs 0%; p<0.0001; OR: Infinity) 
and GSTT1 null (75% vs 28%; p<0.0001; OR: 7.71; CI 3.83 to 15.56) mutated 
genotypes among SCA patients, while the normal genotypes were associated 
with SCA absence. Furthermore, we found GSTP1 114TT mutated genotype 
(52% vs 27%; p=0.003; OR: 2.88; CI: 1.41 to 5.89) and   GSTT1 null genotype 
(87% vs 65%; p=0.003; OR: 3.66; CI 1.51 to 8.84) associated with colon 
samples. 
 
These findings suggest a positive association between most of common 
polymorphisms involved on oxidative stress regulation and SCA prevalence. 
Dysregulation of MNSOD, SOD3, GSTP1, GSTT1 and GSTM1 genes could be 
associated with an increase of ROS in colon and rectum tissue and p53 
pathway deregulation, induced by oxidative stress on colonic and rectal cells. 
The present study also provides preliminary evidence that MNSOD 175C, 
SOD3 213G, GSTP1 105G, GSTP1 114T and GSTT1 null polymorphisms, may 
be involved in SCA risk and could be useful to clarify this multifactorial disorder.  
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1 
I. Introduction 
 
1.1. Colorectal Cancer  
 
Cancer is characterized by uncontrolled growth and spread of mutated cells 
(Figure 1). External factors (such as alcohol and radiation), as well, internal factors 
(such as hormones and mutations) may trigger initiation and promotion of 
carcinogenesis.1-5 When tumor progression is uncontrolled, it can result in fatality. 
However, prevention can be achieved in certain types of cancer by inhibiting the 
effects of these factors. Research shows that environmental factors, such as diet, 
influence gene expression control mechanisms (for example, epigenetic 
processes) that can eventually lead to the development of malignant disease.1-5 
Studying the impact of nutrients on genes, their encoded proteins and the 
influence of genetic factors on diet is essential for the development of strategies of 
prevention.  
 
Colorectal cancer (CRC) is the second major cause of death on the 
developed countries and the second more incident in both genders (Figure 2).6 
The incidence of CRC patients and their overall survival change between 
countries, ethnic groups and lifestyles.1-4 The interaction between diet and other 
environmental factors with genetic factors can explain the difference in incidence 
between geographic regions.1-4 Mortality by CRC has increased approximately 
Figure 1: Carcinogenesis process. 
Adapted from: http://csls-text2.c.u-tokyo.ac.jp/large_fig/fig07_01.html 
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80% during the last two decades of the 20th century.5 Based on statistics from data 
of 2012, CRC is responsible for 13% of death by in Europe and its 16% of the total 
oncologic mortality rate in Portugal. In Portugal CRC have the 2nd higher mortality 
after lung in males and breast cancer in females (Figure 3).6 
 
 
Figure 2: Cancer incidence in Portugal by World Health Organization (2014). 
Adapted from: http://www.who.int/nmh/countries/prt_en.pdf?ua=1. 
Figure 3: CRC incidence in males and females in Portugal by World Health 
Organization (2014). Adapted from: http://www.who.int/nmh/countries/prt_en.pdf 
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1.2. Types of Colorectal Cancer 
 
There are three known types of this disease: sporadic forms, inherited 
syndromes and family forms.7,8 Approximately 10%-30% of all CRC cases occur in 
the context of a family history (such as Lynch Syndrome) but the predisposing 
genetic factors are still unknown. Familial adenomatous polyposis (FAP), MYH-
associated polyposis (MAP), and hereditary nonpolyposis colon cancer (HNPCC), 
which are highly penetrant and inherited CRC syndromes, are less common 
examples, accounting for up to 5% of CRC cases. 9-11 These cases result from 
mutations highly associated to specific genes that lead to the development of two 
distinct syndromes: familial adenomatous polyposis (germinal mutation in APC 
gene) and non-associated polyposis colon inherited carcinoma (Syndrome of 
Lynch - germinal mutations in genes involved in DNA repair).12-14 The 
accumulation of these mutations results from an inactivated repair system, and 
this is defined as the mutant pathway of carcinogenesis.15 When there is a medical 
history of CRC in a relative of first and second degree the risk increases to 20%, 
and in individuals who present one of the syndromes referred before, the risk 
reaches 80-100%.16 In spite of the familial cases, approximately 70% of CRC 
cases occur occasionally, indicating that health behaviors are strongly correlated 
to disease development. 17,18 
Sporadic form of CRC (Sporadic Colorectal Carcinoma - SCA) is 
characterized by accumulation of mutations, loss of function of several tumor 
suppressor genes and activation of oncogenes. 19 These oncogenes are involved 
in regulation of cell proliferation and tumor suppressor genes. Gain-of function of 
oncogenes and loss-of-function mutations in tumor suppressor lead to altered cell 
proliferation.20,21 In SCA, random mutations during carcinogenesis follow a well-
Figure 4: Multistep model of Colorectal carcinogenesis. 
Adapted from: http://csls-text2.c.u-tokyo.ac.jp/large_fig/fig07_04.html 
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established sequence (Figure 4). The inactivation of APC gene located in 
chromosome 5 is the first step to dysplasia in an adenoma. Additional mutations 
accumulate in oncogenes (RAS family) and tumor suppressor genes in 
chromosomes 18q (DCC, SMAD2, SMAD4) and 17q (p53), leading to an 
accentuated dysplasia and subsequently to carcinoma.22  
It is also know that colitis associated to CRC has a contribution to 
carcinogenesis. The mutation and transformation process of a normal into a 
cancer cell can be triggered by accumulation of free radicals at the early stages 
and result in cancer progression. Generally is a slow process and often takes 
decades from tumor initiation to diagnosis.23  
 
 
1.3. Environmental factors: antioxidant nutrients 
 
 
Diet and environment have been recognized as main factors to CRC 
development risk. It is known that low physical activity, a rich diet in fats and 
sugars and poor in food fibers, as well smoking habits were associated with a 
greater CRC risk. On the other hand, high consumption of vegetables and an 
active life have been associated with a low risk. 24-27 Various nutrients with either 
pro-inflammatory or anti-inflammatory activities may work together to influence 
CRC risk. High consumption of processed and red meats, refined grains, soda, 
and sweets pattern has been associated with increased CRC risk. In contrast, high 
intake of fruits, vegetables, fish, poultry, and whole-grain products has been 
associated with lower risk. Glutathione, carotenoids (β-carotene, vitamin A and 
lycopene), vitamin C, vitamin E and flavonoids have potent anti-oxidative and anti-
inflammatory properties, which confers protective effects against oxidative stress 
and tumorigenesis.  Prospective studies have shown that antioxidant nutrient 
intake is associated inversely with CRC risk and can reduce adenoma recurrence. 
However, antioxidant intake may be essential for overall health, but is unlikely to 
prevent CRC. 27-32  
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Among CRC patients, higher intake of a Western dietary pattern after 
diagnosis may increase the risk of cancer recurrence and mortality, while a 
Mediterranean diet has been associated with lower cancer mortality and lower 
CRC risk.27 Despite of the consistent associations between CRC and some food 
behaviors (diet, smoking habits, physical activity), there are several 
inconsistencies which suggest that genes variants (polymorphisms) are involved 
on body individual responses to their behavior. These inconsistencies can reflect 
the complex and multifactorial genesis of this pathology (Figure 5). Furthermore, 
polymorphisms can interfere with bioactive process, absorption and elimination. 
Molecular targets and their distribution can be altered, as well. In this view, at first, 
it is essential understand the interaction between those factors and their role in 
CRC development. 33-36 
Figure 5: Main sources of ROS production. 
Adapted from: http://transformationalwellnessproject.blogspot.pt/2014/03/topic-2-
reduction-oxidation-free.html 
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Inflammation, fat metabolism, meat consumption, alcohol and tobacco 
smoking are the main factors in CRC genesis by reactive oxygen species (ROS) 
release (Figure 6). Activated macrophages during inflammation, oxidation of 
polyunsaturated fatty acids, intake of heme present in red meat release large 
amounts of ROS and reactive nitrogen species (RNS) witch oxidize DNA/RNA, 
proteins and lipids and induce DNA damage and cell proliferation of colonic 
epithelial cells.  High levels of insulin and glucose, in combination with oxidative 
stress and chronic inflammation, can increase the risk of developing cancer 
amongst patients with diabetes.28 Although controversial, epidemiologic studies of 
tobacco smoking have demonstrated high levels of oxidative damaged in the 
leukocytes of lung cancer patients. However the molecular mechanism of 
development of CRC remains unclear.29 
 
1.4. Oxidative stress 
 
There are several metabolisms involved in cancer beginning. From those, 
the redox metabolism has been one of the most studied on cancer research. 
Redox homeostasis is maintained by regulated production of redox active 
molecules. Imbalance on this metabolism leads to an overproduction of ROS, 
increasing the rates of cellular oxidative stress.28-30, 37-42 ROS are molecules or 
ions formed by the incomplete one-electron reduction of oxygen.  Mitochondria are 
essential for the production of energy inside the cell. This is the most important 
Figure 6: Risk factors to CRC carcinogenesis. 
Adapted from: http://www.who.int/nmh/countries/prt_en.pdf 
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source of ROS. They are unstable metabolites of molecular oxygen (O2) that have 
high reactivity, such as, superoxide radical (O2
-), hydroxyl radical (HO-) and 
hydrogen peroxide (H2O2). These species are generated as byproduct of normal 
aerobic metabolism. In balance conditions, they contribute to microbicide activity 
of phagocytes, regulation of signal transduction and gene expression. 32,43,44  
Oxidative stress is defined as overproduction of reactive oxygen species 
combined with failure in protective mechanisms of redox defense. The 
concentrations (threshold), pulse duration (flux) and sub-cellular localization are 
responsible for their responses (Figure 7).32,44,45 Low or moderate concentrations, 
reactive oxygen species act as mediators/second messengers of specific 
physiological processes and signaling pathways regulating numerous cellular 
processes, including proliferation and apoptosis. However, ROS and RNS high 
concentrations can be responsible for: damage on DNA, RNA, proteins and 
chromosome degradation; polyunsaturated fatty acids and amino acids oxidation; 
enzymatic inactivation, abnormal inflammatory reactions and interfere on cell-
signaling molecule, such as apoptotic regulators and antioxidant enzymes. Those 
alterations seem to be associated with the initiation or progression of human 
cancers by the disruption of cell, tissue or organ functions (Figure 8). 28, 29, 41, 42, 44, 
46-51  
 
Figure 7: Reactive species concentration and their responses. 
Adapted from: Graves DB. The emerging role of reactive oxygen and nitrogen 
species in redox biology and some implications for plasma applications to medicine 
and biology. J Phys D Appl Phys. 2015; 45: 263001 
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Free radicals are molecules with high instability and reactivity due to the 
presence of an odd number of electrons in the outermost orbit of their atoms. Cells 
can generate ROS from exogenous sources as well as endogenously. 
Endogenously ROS production results mainly from the mitochondrial electron 
transport chain but also from proteins metabolism (metabolism of fatty acid, 
xanthine oxidases, cytochrome P450 reductase, nitric oxide synthase, 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidases, peroxisomes 
and myeloperoxidase.23, 41, 44, 51, 52 Molecular oxygen is the last electron acceptor 
during oxidative phosphorylation. Incomplete reduction of O2 in the mitochondrial 
electron transport chain can lead to accumulation of O2
−, OH- and H2O2, which as 
highly reactive species.30,43 
 
 
 
 
Figure 8: ROS-mediated mechanisms in carcinogenesis. 
Adapted from: Trachootham D. Alexandre J. Huang P. Targeting cancer cells by ROS-
mediated mechanisms: a radical therapeutic approach? Nature Reviews Drug 
Discovery.2009: 8, 579-591 
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1.5. Genetic Factors: Oxidative stress regulators  
 
Nowadays, we know that human gene sequence is shared for 99,9% of 
individuals and the slight variation is essentially in just one nucleotide (SNPs - 
small nucleotide polymorphisms). 87 Polymorphism is variation in a gene or in DNA 
that occurs with a relative high frequency on population. The recent medicine 
attempts to relate those polymorphisms with the individual response to diet 
behavior, tobacco and alcohol consumption with disease predisposition. Noting 
that individual genetic constitution alters individual response to bioactive 
components.38, 39, 53-59 On this view, in last years it has been reported several 
variations, directly involved or not, involved in metabolic pathways with direct risk 
to CRC development.25-27, 33-36, 60-63 
Eukaryotic cells have developed defense mechanisms that eliminate ROS. 
The human’s antioxidant endogenous defense system consists in a range of 
extracellular and intracellular antioxidants that are able to protect tissues from 
ROS and RNS.  This antioxidant defense consists in non-enzymatic and 
enzymatic system. Non-enzymatic antioxidants are nutrient compounds, which 
includes: fenol, glutathione, vitamins C and E, β-carotene, α-tocopherol, and 
cytochrome c. Enzymatic process includes antioxidant enzymes, such as 
superoxide dismutase (SOD), glutathione reductase (GSSRG-R), glutathione 
peroxidase (GSH-Px), glutathione S-transferase (GST), and catalase (CAT). SOD 
catalyzes the dismutation of superoxide anion (O2
-) into hydrogen peroxide (H2O2) 
plus O2. GSH-Px and catalase reduce H2O2 to O2 and H2O (Figure 9). GSH-Px 
uses glutathione as a reducing agent (electron donor). 23, 32, 41, 42, 45, 47, 48, 51, 64-68, 69, 
70 
Figure 9: ROS elimination process. 
Adapted from: Bigarella CL. Liang R. Ghaffari S.. Stem cells and the impact of ROS 
signaling.  Development. 2014; 141(22): 4206–4218. 
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Some genes have polymorphic variants, single nucleotide polymorphisms 
(SNP) that are responsible for the individual’s genetic constitution/response. 
Between the genes with antioxidant and detoxifying activity, superoxide 
dismutases (SOD) and glutathione-S-transferases (GST) genes are highly 
polymorphic and often contain numerous mutations, increasing the risk of the 
cancer development on esophagus, stomach, large intestine, breasts, lungs and 
lymph nodes.39, 48, 53-56 Thus, we can suppose that some polymorphisms, involved 
in oxidative stress regulation, may predispose to disease and particularly on CRC.  
The strength of the biological impact will also depend on heterozygosity or 
homozygosity of the variant allele.71 
 
 
1.5.1. Antioxidant regulators - Superoxide Dismutases 
 
It is assumed that carcinogenesis is a result of cellular proliferation and 
differentiation control loss. Superoxide dismutase genes seem to have an 
important role on oxidative metabolism balance, particularly in cellular detoxify. 
SODs are a family of enzymes, responsible for the first line of antioxidant defense 
against ROS.67,72 In humans there are three main isoforms of these genes: SOD1, 
SOD2 and SOD3 (Figure 10). They encode proteins that require copper, zinc or 
manganese on their active center in order to their enzymatic function, respectively 
SOD1, SOD3 (Cu/Zn- SOD) and SOD2.  O2
- dismutation mechanism into H2O2 by 
SOD, which involves alternate reduction and re-oxidation of these metals.73 SOD1 
is located in the cytosol of liver, kidney, erythrocytes, and central nervous system 
cells – mutations on this enzyme are associated with neural diseases, such as 
amyotrophic lateral sclerosis. SOD2 is found in mitochondria and it’s associated 
with aging, cancer, asthma and transplant rejection as well. SOD3 is detected as 
extracellular enzyme, plays an important role in regulating blood pressure, 
vascular contraction and also in neurologic, pulmonary and arthritic diseases. 
SODs catalyze the inactivation (dismutation) of superoxide ion by convert in 
oxygen peroxide, a less toxic molecule. 23, 38, 39, 43, 56, 64, 74, 75 
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There is evidence that decreased of intracellular SOD levels are related to 
malignant transformation, nevertheless, this data was not reported for SOD1.67, 72, 
76 In the past, it was supposed that induction higher levels of SOD causes a return 
to the non-malignant phenotype.51, 65 Nowadays, it was found that manganese-
dependent superoxide dismutase (MnSOD) or SOD2 overexpression appears to 
enhance invasiveness and migration of malignant cells.38,39 Moreover, several 
studies have reported that SOD2 is upregulated during tumor progression in 
prostate, colon and lung.47  On the other hand, other studies report that SOD2 
overexpression can suppress tumor incidence and proliferation in other cancers 
such as in breast and skin cancers. Innumerous polymorphic variants of these 
genes confer different expression and active proprieties on antioxidant cellular 
defense.38, 39, 53-56 In colon cancer mutations, adenomatous polyposis, could begin 
a neoplasia process even when SOD2 levels are often low. The SODs activities 
are often lowered during early cancer development. However, SOD2 mRNA and 
protein levels increase during early and intermediate stages in lung and colorectal 
cancers.42, 47, 67, 69, 76, 77  
Figure 10: Role of SODs in oxidative metabolism balance. 
Adapted from: http://cdn.intechopen.com/pdfs-wm/38459.pdf 
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 SOD2 gene 
The role of SOD2 is still not exactly understood. SOD2, also named as 
MnSOD, regulates cellular redox homeostasis that is known to regulate 
proliferative and quiescent growth states. SOD2 expression is induced by a wide 
variety of factors such as hyperoxia, irradiation, cytokines (IL-1, TNF-α), oxidized 
LDL and the cellular redox state. Disturbances in the functioning of SOD isoforms 
lead to numerous pathological changes in the human organism, including tumor 
disease. Therefore, MnSOD and ROS rates are believed to be critical regulators.41, 
43, 50, 65-67, 76  
 
The SOD2 gene located in chromosome 6q25, it’s the most well-known 
(Figure 11).27, 43, 64, 76 The Val16Ala (47 T>C; rs4880) polymorphism has a single 
peptide mutation, a substitution of a valine acid for an alanine amino acid on its 16 
codon. This mutation leads to a conformational change in the helical structure of 
the protein.23,31 It is predicted that the Ala variant encodes proteins with a higher 
MnSOD activity than the Val variant, suggesting that Ala/Ala homozygous subjects 
may have higher SOD2 activity. Therefore, the defense response to oxidative 
stress will be altered as well.23, 27, 31, 64, 76 It is hypothesized that the higher activity 
variant (Ala) suppresses carcinogenesis; however, this overproduction of SOD2 
increases the levels of H2O2, as well. Epidemiologic studies associated the Ala 
variant with increased risk of carcinogenesis, particularly among people with lower 
intakes of exogenous antioxidants on their diet.43, 76, 78 
There are several different views on how MnSOD expression can contribute 
to cancer development. Several authors reported that a loss of MnSOD activity 
results in aberrant proliferation, and was also related with poor 5-year overall 
survival.31, 41, 65, 67, 68 One explanation for such discrepancies is the different clinical 
stages of the tumors studied.66 CRC have been characterized 
Figure 11: Genomic view of MnSOD gene. Adapted from: 
http://cdn.genecards.org/images/v4/genomic-location/SOD2-gene.png 
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immunohistochemically by a decreased of MnSOD and total SOD activity when 
compared with adjacent normal mucosa, suggesting that MnSOD acts a tumor 
suppressor.50 There are authors that showed a decreased or unchanged 
expression and activity of SOD isoenzymes.43, 65, 74 While others observed 
increased expression and activity of SOD isoenzymes in various types of tumors, 
implying MnSOD in tumors progression, aggressiveness and metastatic 
potential.66, 67, 72 MnSOD overexpression has shown to slow down cancer cell 
growth, but it also has a metastasis-promoting activity by the upregulation of 
matrix-degrading metalloproteases and blocking apoptosis.44, 68, 78 
 
 SOD3 gene 
Extracellular superoxide dismutase (EC-SOD; SOD3) has Cu and Zn in the 
catalytic center and a heparin binding domain (HBD). SOD3 is highly expressed in 
plasma, blood vessels, heart, lungs, kidney, placenta and extracellular fluids. This 
enzyme is produced by resting macrophages and it’s associated with the cell 
surface through extracellular matrix (ECM)-binding region.76 SOD3 is a protective 
molecule which catalyzes the conversion of superoxide anions into hydrogen 
peroxide and oxygen, thus protecting from oxidative fragmentation of matrix 
components. Inherited change in SOD3 expression or function could affect organ 
matrix homeostasis and influence its normal function.23, 31, 73, 76, 79, 80 SOD3 binds 
matrix components and inhibits their fragmentation in response to oxidative stress.  
Their fragmentation stimulate inflammatory cell migration, so SOD3 could play a 
central role in tissue defenses against oxidative stress.23,79 It was observed that 
non-neoplastic tissue has more SOD3 expression than neoplastic tissue which 
supports the previously predicted role of SOD3 in tumorigenesis. Thus, 
dysregulation of extracellular oxidant-moderating proteins, such as SOD3, is 
significant in cancer. However, there is not much knowledge about EC-SOD in 
human tumors so further studies are needed in order to characterize its potential 
role.81, 82, 83 
The most studied single nucleotide polymorphism (SNP) within SOD3 is 
Arg231Gly (rs1799895; R213G) on chromosome 4 (Figure 12). About 2-3% of the 
population carries this polymorphism. The substitution of arginine to glycine in its 
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heparin binding domain at amino acid 213 (R213G) was first identified in patients 
with heart failure.31, 73, 81, 82 This variant is known to reduce the binding capacity of 
SOD3 and may thus have an impact on the cellular distribution.68, 76 Transcript 
levels of SOD3 significantly differed between tumor and non-neoplastic tissues. A 
low expression level of SOD3 induces primary cell proliferation and 
immortalization, whereas, high expression levels induce growth arrest, 
senescence, and apoptosis though signaling pathway activation (p53 and p21).84, 
85 Despite the enzymatic activity of SOD3 should not be affect by this mutation, it 
was observed in lung adenocarcinoma that SOD3 mRNA and protein expression 
were significant decreased.75, 85  
 
 
While SOD2 was upregulated in the tumor tissue, this SOD3 polymorphism 
leads to a higher concentration of SOD3 in plasma and lower in tissues, once it’s 
anchoring/binding to the extracellular matrix is compromised. Thus SOD3 has 
strong downregulation in tumor tissue samples.31, 78, 82, 86  Evidence of 
downregulation in SOD3 expression in lung and oral tumors, previously reported, 
have suggested that SO3 can have potential effects on extracellular regulation of 
multiple factors that regulate angiogenesis and invasion, increasing relative risk for 
this disease.73, 77-80, 82-84, 87 It was reported that SOD3 overexpression, delays the 
onset of increased breathing frequency and significantly reduces breathing rates in 
wild-types mice exposed to a source of oxidative stress (ionizing radiation).78 
SOD3 overexpression also inhibits the invasive capacity of human prostate cancer 
cells.82 78 Therefore, arginine 213 is critical for maintaining proper organ function 
through moderating the normal innate immune response, suggesting the potential 
to suppress aggressive tumor behavior.78, 80, 82, 86 
1.5.2. Detoxify regulators: Glutathione S-transferases 
Figure 12: Genomic view of SOD3 gene.  
Adapted from: http://cdn.genecards.org/images/v4/genomic-location/SOD3-gene.png 
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Glutathione S-transferases (GSTs) super family is a family of 
Phase II detoxification enzymes that are involved in the 
detoxification of xenobiotic compounds. They catalyze the 
conjugation of glutathione (GSH) to a wide variety of endogenous 
and exogenous electrophilic compounds (Figure 13) formed during 
oxidative stress including those result from lipid peroxidation. 88-103 
 
  
 
This process usually inactivates the electrophiles and facilitates their 
excretion into urine or bile.88, 89 On the other hand, this detoxification ability plays 
an important role in cellular protection from environmental and oxidative stress, yet 
is also implicated in cellular resistance to drugs acquired by an accelerated 
detoxification of drug substrates.90 The GSTs are found on liver and in the 
epithelium of the human gastrointestinal tract, thus providing a protective role for 
the cells in the gut.88, 104, 105 GST activities may be reduced in colonic mucosa 
affected by chronic inflammatory conditions.105 GSTs have also been shown to 
play critical roles in kinase signaling. However, this pathway is not fully 
understood. The lack of function of these enzymes has been correlated with a 
higher risk of cancer. Studies have linked aberrant expression of GST isozymes 
with the development and expression of resistance to a variety of chemicals. 
Therefore, differences in the human GST isozyme expression patterns influence 
cancer susceptibility, prognosis and treatment.38, 53, 54, 88, 91-96, 98, 99, 100, 102, 106-108  
Glutathione S-transferases are high polymorphic among ethnicities. Human 
GSTs are divided into three main families with have similar ability to catalyze the 
conjugation of GSH: cytosolic, mitochondrial and membrane-bound microsomal. 
Based on identity sharing greater than 60% within a class and focuses mainly on 
the highly conserved N-terminal, the mammalian cytosolic family of GSTs is further 
Figure 13: Graphic representation of GSTs detoxify role. 
Adapted from:  Gorrini C. Harris IS.  Mak TW. Modulation of oxidative stress 
as an anticancer strategy. Nature Reviews Drug Discovery 2013;12: 931–947 
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divided into seven classes: alpha, mu, omega, pi, sigma, theta and zeta.90, 94, 96-98, 
101, 104, 108-110 
Recently, was described plus one class – lambda (K).103 From these 
classes above, alpha, mu, theta and pi have been identified in the human colon; 
however, the pi class predominates.105, 110, 111 SNPs in those isoforms cause a 
steric change at the substrate-binding site of the enzyme that changes its catalytic 
activity which seems to denote impaired ability to detoxify carcinogens, conferring 
an increased cancer risk.90, 110, 112 
 
 
 GSTP gene 
The GST Pi class is encoded by a single gene located on chromosome 11 
(Figure 14). Four functionally different polymorphisms have been identified 
(GSTP1*A–D). For GSTP1, two genetic polymorphisms are known for this gene: in 
exon 5, a substitution A>G at codon 105 of GSTP*B gene (Ile105Val; rs1695), 
turns amino acid isoleucine to valine; in exon 6, transition of C>T at codon 114 
turns in a substitution of amino acid alanine to valine (Ala114Val; rs1138272).27, 90, 
94-97, 106-108,110, 111 These SNPs cause a steric change at the substrate-binding site 
of the enzyme that changes its catalytic activity without affecting the binding 
affinity to glutathione.90, 110  
 
The GSTP1 genotype has been associated with differences in 
chemotherapeutic response and cancer susceptibility and is overexpressed in a 
wide variety of tumors including ovarian, bladder, testicular, lung, breast, colon, 
pancreas, larynx and lymphoma.94, 95, 97, 105, 110 GST expression and/or activity of 
Figure 14: Genomic view of GSTP gene.  
Adapted from: http://cdn.genecards.org/images/v4/genomic-
location/GSTM1-gene.png 
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specific isoforms are lost in some individuals with allelic variation and are 
proposed to occur during pathogenesis of the disease. Lack of GSTP1 expression 
results on enzyme activity reduction, followed by an increase of cellular oxidative 
stress which allows the human colon cancer cell survival and proliferation.94, 102, 110 
The Ile105Val results in a catalytic activity reduction and thus a diminished 
detoxification capacity in individuals V105 when compared with I105.97,112 It was 
observed a slightly better survival in GSTP1 Ile/Ile patients compared with patients 
with the Ile/Val or Val/Val genotypes.98,112 However, the association between the 
Glutathione S transferase-P1 (GSTP1) Ile105Val polymorphism and colorectal 
cancer (CRC) susceptibility are still inconsistent between studies.102, 106, 110 GSTP1 
Val114 polymorphism apparently contributes to esophageal and colorectal cancer 
susceptibility.102, 110  
 
 GSTT gene 
  
The Theta class of GSTs consists of two different subfamilies: GSTT1 and 
GSTT2. Genes encoding both proteins are localized on chromosome 22 (Figure 
15). Polymorphisms exist within both genes. GSTT1 has a functional and a non-
functional allele. Homozygosity for the nonfunctional allele of GSTT1 is the null 
phenotype and exhibits an absence of catalytic activity. Individuals homozygous 
for this deletion are thought to be at increased risk for malignancies (such as 
cancer, cardiovascular and respiratory diseases) as a consequence of a 
decreased capacity to detoxify possible carcinogens.95, 94, 99, 101-104, 113, 114 It was 
demonstrated that 20% of Caucasians carries this genotype.114 The GSTT1 
polymorphism was significant in breast cancer and for CRC risk in Caucasians.95, 
101, 115 However, this association is not consistent between all studies reported. 
Figure 15: Genomic view of GSTT gene. 
Adapted from: http://www.ncbi.nlm.nih.gov/gene/2952 
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 GSTM gene 
 
Five GSTM isoforms belonging to the mu class (GSTM1- 5) have been 
described. A gene cluster located on chromosome 1 encodes for GSTM1-5, four 
different alleles allowing for several M1 class polymorphisms (Figure 16). The 
presence of the GSTM1 allele has been associated with a decreased risk of 
bladder cancer.91, 94, 104 Loss of GSTM enzyme function is described to a 
homozygous deletion of this gene resulting in the GSTM1 null allele. It was 
showed that 20-50% of Caucasians carries GSTM1 null genotype.114, 115 The 
GSTM null phenotypes are associated with an increased risk of the lung, head, 
colon and bladder cancer and were also been associated with response rates to 
some chemotherapy.  Data have suggested that GSTM1 polymorphism is 
associated with an increased risk of CRC, especially in the Caucasian 
population.88, 89, 94-96, 99, 103-105,108, 114   
 
 
1.6. Antioxidant and Detoxify regulators in colorectal cancer 
 
The gene variants can affect the risk of sporadic colorectal cancer 
associated with various environmental and dietary factors. Diet and social 
behavior are a fundamental risk factor for development of CRC, and its influence 
appears to be stronger during post-initiation phases of carcinogenesis. 
Accordingly, antioxidant and detoxify molecular mechanisms should be considered 
among potential risk modulators for this neoplasia. Several gene polymorphisms 
involved in regulation detox defense. However, there still inconsistencies on CRC 
ethology.  
Figure 16: Genomic view of GSTM gene.  
Adapted from: http://cdn.genecards.org/images/v4/genomic-location/GSTM1-gene.png 
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Both antioxidant and detoxify genes are crucial to redox hemostasis. 
Imbalance on these defense mechanisms leads to ROS accumulation and 
predispose DNA cell to damage.  This damage can change protein activity and 
function.  ROS accumulation on colorectal environment predisposes to risk of 
CRC. The balance between antioxidants and ROS is lost. Therefore, colonic and 
rectal cells will be prone to DNA damage. This damage induces changes on 
enzymatic function and activity. The continuous exposure of colonic and rectal 
cells to ROS damage will allow to neoplasic development (Figure 17). The 
MNSOD, SOD3, GSTP1, GSTT1 and GSTM1 genes have an important role in 
antioxidant and detoxify metabolisms management. Numerous studies reported 
that their polymorphic variants have an huge impact on their functions. However, 
some studies about association and influence on CRC didn’t agree with majority.  
  The knowledge about detox genes polymorphisms involved on CRC 
genesis and development will be essential for new approaches on cancer 
research. However, Sporadic Colorectal Adenocarcinoma (SCA) origin hasn’t 
been studied until now. Therefore, we wanted verify if MNSOD, SOD3, GSTP1, 
GSTT1 and GSTM1 gene polymorphisms influence the risk of SCA occurrence. 
Moreover, we want to know if those polymorphisms are associated to gender and 
colonic and rectal localization among SCA subjects. 
  
Figure 17: Colonic and rectal cells neoplastic development induced by continuous 
ROS exposure. Adapted from: Bigarella CL. Liang R. Ghaffari S.. Stem cells and the 
impact of ROS signaling.  Development. 2014; 141(22): 4206–4218. 
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II. Material and methods 
2.1. Material 
 
 A global of 68 samples of SCA (mean age of 67 +/- 18 years; 75% men 
and 25% women) was used in the research of the defined polymorphisms (Table 
1). A total of 31 colon and 37 rectal biopsies suffered the typical process of fixation 
in formaldehyde and inclusion in paraffin and were selected from the archives of 
Anatomical Pathology Institute of Faculty de Medicine of University of Coimbra 
(Figure 18). Samples were collected between 2009 and 2011, tumor diagnosis and 
differentiation grade of the tumor were established by histological evaluation of 
tumor fragments using criteria according to World Health Organization (Table 2).  
A total of 100 healthy subjects biopsies (with normal colic mucosa) were 
used as control group (mean age of 73 +/- 9 years; 79% men and 21% women) 
(Table 1). This study was supported and approved by local ethics committee 
(CIMAGO - Faculty of Medicine of the University of Coimbra, Coimbra, Portugal). 
 
 
Table 1: Clinical data of SCA and control samples. 
 
 
     Tumor location 
  Distribution Age Colon Rectum Total 
  % Mean Stand. Dev. n % n % 
 
 Gender 
 
  
     
Patients 
Male 75 
67 18 
25 81 26 70 51 
Female 25 6 19 11 30 17 
 
Total 100   31 100 37 100 68 
Controls 
Male 79 
73 9 
     
Female 21      
 Total 200        
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Figure 18: (A) and (B) Histologic picture of normal colonic mucosa: 40x HE, 200x HE; 
(C) and (D) – Histological picture of well differentiated sporadic adenocarcinoma. 200x 
HE (hematoxylin-eosine); 100x HE. Images from IAP-FMUC. 
 
  
 
 
 
A B 
C D 
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Histological classification according to WHO 
Epithelial tumours   Non-epithelial tumours  
          
Adenoma     Lipoma    
  Tubular   Leiomyoma    
  Villous   Gastrointestinal stromal tumour 
  Tubulovillous   Leiomyo sarcoma    
  Serrated   Angiosarcoma    
      Kaposi sarcoma   
Intraepithelial neoplasia (dysplasia)  
associated with chronic inflammatory 
diseases 
  
  Malignant Melanoma    
  Others   
  
Low-grade glandular 
intraepithelial neoplasia   
 
  
  
High-grade glandular 
intraepithelial neoplasia   
 
  
    
Malignant lymphomas 
  
Carcinoma       
Marginal zone B-cell 
lymphoma of MALT Type  
  Adenocarcinoma      Mantle cell lymphoma  
  Mucinous adenocarcinoma      
Diffuse large B-cell 
lymphoma 
  Signet-ring cell carcinoma      Burkitt lymphoma  
  Small cell carcinoma      
Burkitt-like /atypical Burkitt-
lymphoma  
  Squamous cell carcinoma      Others 
  Adenosquamous carcinoma        
  Medullary carcinoma        
  Undifferentiated carcinoma   
Secondary tumours 
  
          
      Polyps   
Carcinoid (well differentiated endocrine 
neoplasm)       
  
EC-cell, serotonin-producing 
neoplasm    
Hyperplastic (metaplastic) 
  
  
L-cell, glucagon-like peptide 
and PP/PYY producing tumour   Peutz-Jeghers   
  
 
  Juvenile   
  
Mixed carcinoid-
adenocarcinoma        
  Others       
Table 2: Tumor grade according to World Health Organization. 
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2.2. Methods  
2.2.1. DNA extraction 
DNA genomic isolation from biopsies were made according to the extraction 
protocol from NZY Tissue gDNA Isolation Kit (NZYTech, Lisbon, Portugal), after 
microdissection of the normal colic tissue (5 to 10 dissections of 10µm of thickness 
to each sample). Samples were prepared by adding 1 ml of xylene to each tube to 
paraffin removal. After centrifugation at 11,000xg for 3 min, supernatant was 
discarded and samples were washed with 1ml of ethanol (96%-100%), repeating 
the centrifugation step.  Lysis of the cell wall by Proteinase K and NZY was then 
performed overnight and purification of DNA obtained through columns and 
according to the procedure of the referred kit. The DNA was further stored at – 
20ºC. 
 
2.2.2. Analysis of concentration and quality of the extracted DNA 
DNA samples were quantified in a spectrophotometer GeneQuant pro 
(Biochrom, Cambridge, England). RNAse-free water was applied as reference and 
7 μl of DNA sample were inserted in the ultra-microvolume cuvette in order to 
perform the quantification and measurement of concentration and purity of the 
sample, by reading adequate optical densities (230 nm, 260 nm and 280 nm). The 
existence of nucleotides and proteins was detected at a wavelength of 280 nm, 
while at the 260 nm wavelength there is detection of nucleotides only. At a 
wavelength of 230 nm, the presence of contaminants is assessed.   
 
2.2.3. Genotyping 
The genotyping of polymorphisms was carried through commercial kits 
“Nutri Box Kit” (Genebox, Cantanhede - Portugal) using PCR-SSP technique. 
These kits included internal, negative and positive controls for each sample. 
MNSOD T175C, SOD3 R213G, GSTP1 A105G, GSTP1 C114T, GSTT1 del, 
GSTM1 del mutations detection was performed using manufacturer protocol 
(Table 3). The amplified PCR products was analysed by electrophoresis with a 
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SYBR Safe (Molecular Probes, Oregon – USA) in 2% agarose gel and visualized 
in a ultra-violet (UV) transilluminator (UVi Tech, Cambridge, United Kingdom). 
Step Temperature Time Number of cycles 
Initial denature 95º C 1 Min 1 
Denature 
Annealing 
Extension 
95º C 
70º C 
72º C 
25 Sec 
45 Sec 
30 Sec 
 
5 
Denature 
Annealing 
Extension 
95º C 
65º C 
72º C 
25 Sec 
45 Sec 
30 Sec 
 
21 
Denature 
Annealing 
Extension 
95º C 
55º C 
72º C 
25 Sec 
1 Min 
2 Min 
 
4 
Final extension 72º C 10 Min 1 
 
Table 3: Protocol of amplification by PCR-SSP (Polymerase Chain Reaction – Single Specific 
Primers), from Genebox, Cantanhede – Portugal. 
 
 
2.2.4. Electrophoresis in agarose gel 
 
PCR reactions, after amplification, were submitted to electrophoresis by 2% 
agarose gel in order to identify the amplified products. Agarose Routine Grade 
(NZYTech, Lisbon, Portugal) was dissolved in 1x TAE (Tris-acetate-EDTA) 
(NZYTech, Lisbon, Portugal) and distillated water and agitated for 15 seconds. 
Then the solution was transferred to the microwaves to complete dissolution of 
agarose (approximately 2 min at 900w). Afterwards, the solution was cool down 
and 1x10-5 SYBR Safe (Molecular Probes, Oregon – USA) a dye that allows the 
visualization of DNA under the UV light incidence, were added and the solution 
was agitated for 15 seconds for homogenization. Solution was after putted into a 
cradle until it solidifies under the environment temperature. After solidification, the 
solidified gel was inserted in the plastic gel box, previously filled with 1x TAE 
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(NZYTech, Lisbon, Portugal). PCR samples were inserted into the gel wells and 
they were left running for 10 minutes under the 300 volts of the Power Pac Basic 
device (Bio-Rad, California, USA). Finally, PCR products were visualized under 
UV light by a transilluminator (UVi Tech, Cambridge, United Kingdom). Results 
were further registered by a digital camera (NIKON DMX1200F). 
 
2.2.5. Statistical analysis 
2.2.5.1. Analysis of purity and concentration of DNA 
DNAs purity and concentration study consisted on the calculation of the 
means, standard-deviations and confidence levels relatively to their concentrations 
and contamination quantity. This statistical analysis aimed to verify if the conditions 
of the DNAs were acceptable for the validation of the results in the study. 
 
 
2.2.5.2.  Frequencies of allele and genotype polymorphisms 
Allele and genotype frequencies were calculated from obtained percentages 
for each studied polymorphism. In order to assess if the mutations were in 
equilibrium, chi-square test was performed using the Hardy-Weinberg equilibrium 
as reference. MnSOD T175C, SOD3 R213G, GSTP1 A105G, GSTP1 C114T, 
GSTT1 del, GSTM1 del frequencies were compared between different groups 
(SCA versus control and among tumor localization) using STATISTICA 14 
(StatSoft, Inc., 2013) based on chi-square (2x2) test and Exact Fisher test. The 
significance level was set at p<0.05, odds ratio (OR) and 95% confidence intervals 
(CI) for relative risks (RR) were also calculated for each variation. 
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III. Results  
3.1. Clinical pathology data 
 
The individual distributions of the SCA subjects included in the study, 
according to the clinical pathologic and biological features of biological samples 
are presented in the Table 1. The distribution of SCA subjects by gender shows 
the predominance of the disease in male subjects comparing with female 
individuals (75% versus 25%) (Table 1). In terms of tumors localization, it was 
observed a small difference between gender distribution among colon and rectum 
groups, however, no significant differences were found (Table 4). Moreover, 46% 
of the SCA biopsies were located in colon and 54% of the SCA biopsies were 
located in rectum (Table 4). However, there were no significant differences 
between mean age in both groups (patient samples:  mean age of 67 +/- 18 years; 
controls: mean age of 73 +/- 9 years) (Table 1). 
 
 
Colon Rectum 
   
 
n % N % p OR RR 
Male 25 81 26 70 
NS Female 6 19 11 30 
Total 31 46 37 54 
 
Table 4: Gender distribution among colon and rectum groups. 
 
 
3.2. Analysis of purity and concentration of DNA 
Although the concentration of DNA is not uniform (+/-29.3g/ml) and lower 
than the standard value (100 g/ml) (Table 5), the amplification by PCR-SSP 
occurred without problems, as the protocol of amplification was adapted to the 
concentration of DNA of samples. Although the mean values of purity of DNAs 
range between acceptable limits, 1.6-1.8 to O.D.260nm/O.D.280nm and 0.4-0.6 to 
O.D.230nm/O.D.260nm, some DNAs show high quantities of contaminants and 
proteins with a confidence interval being above certain acceptable limits.  
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Furthermore, coefficients of variation show the existence of samples that 
deviate from acceptable patterns, whether in concentration of DNA and whether in 
quantity of contaminants. These DNAs can affect some results; however the 
majority of samples show a level of purity highly acceptable (Table 5). In general, 
PCR-SSP didn’t have major amplification problems. 
 
Concentratio
n 
O.D.260nm/ 
O.D.280nm 
O.D.230nm/ 
O.D.260nm 
Mean 42.4 1.83 0.54 
Standard Deviation 29.3 0.09 0.15 
Variation Coefficient 69% 5% 28% 
Confidence Interval 
(95%)  
1.7-1.9 0.4-0.7 
 
Table 5: Means and standard-deviations of DNA samples purity and concentration values. 
 
3.3. Molecular analysis of antioxidant and detoxify genes 
3.3.1. Polymorphisms in SCA and controls 
 
When compared SCA with controls, we notice that MNSOD 175C 
(p<0.0001; 69% vs 32%; OR:4.76; CI: 2.97 to 7.61), SOD3 213G (p<0.0001; 52% 
vs 25%; OR:3.37; CI: 2.11 to 5.36), GSTP1 105G (p<0.0001; 59% vs 30%; 
OR:3.33; CI: 2.11 to 5.26) and GSTP1 114T (p<0.0001; 53% vs 12%; OR:8.66; 
CI: 5.00 to 15.00) mutant alleles were more frequent among SCA subjects (Table 
6-7; Graphic 1-2). 
Patients and controls 
Alleles 
Patients Controls 
p OR RR 
n % n % 
MNSOD T175 C (rs4880) 
T 42 31 136 68 
<0.0001 
0.21 (0.13-0.34) 0.40 (0.30-0.53) 
C 94 69 64 32 4.76 (2.97-7.61) 2.52 (1.90-3.38) 
Total 136 100 200 100    
 
SOD3 R213G (rs1799895) 
C 65 48 151 75 
<0.0001 
0.30 (0.20-0.47) 0.51 (0.40-0.65) 
G 71 52 49 25 3.37 (2.11-5.36) 1.97 (1.53-2.53) 
Total 136 100 200 100    
Table 6: Allelic frequency of antioxidant genes in SCA and control group. 
 
  
Antioxidant and detoxify genes polymorphisms in colorectal cancer predisposition 
Patrícia Alexandra Sousa Jegundo, 2015 
 
29 
 
 
 
 
 
 
 
 
 
 
 
 
 
Alleles Patients and controls 
Patients Controls 
p OR RR 
n % n % 
GSTP1 A105G (rs1695) 
A 56 41 140 70 
<0.0001 
0.30 (0.19-0.47) 0.50 (0.38-0.65) 
G 80 59 60 30 3.33 (2.11-5.26) 2 (1.54-2.60) 
Total 136 100 200 100    
 
GSTP1 C114T (rs1138272) 
C 64 47 177 88 
<0.0001 
0.12 (0.07-0.20) 0,35 (0.28-0.45) 
T 72 53 23 12 8.66 (5.00-15.00) 2.85 (2.25-3.62) 
Total 136 100 200 100    
Table 7. Allelic frequency of detoxify genes in SCA and control group. 
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Graphic 1: Allelic frequency of antioxidant genes in SCA and control group (p<0.0001). 
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Graphic 2: Allelic frequency of antioxidant genes in SCA and control group (p<0.0001). 
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Graphic 3: Genotype frequency of antioxidant genes in SCA and control group. 
We also found a higher prevalence of MNSOD 175CC (55% vs 2%; 
p<0.0001; OR: 58.5; CI 13.3 to 256.7), SOD3 213GG (31% vs 2%; p<0.0001; OR: 
21.89; CI 4.93 to 97.29), GSTP1 105GG (46% vs 12%; p<0.0001; OR: 6.14; CI 
2.85 to 13.26), GSTP1 114TT (38%  vs 0%; p<0.0001; OR: Infinity) and GSTT1 
null (75% vs 28%; p<0.0001; OR: 7.71; CI 3.83 to 15.56) mutated genotypes 
between SCA patients. GSTM1 del mutated genotype was not statistical 
significance between SCA patients and control group (Table 8-9; Graphic 3-4). 
 
Patients and controls 
Genotypes 
Patients Controls 
p value OR RR 
n % n % 
 
MNSOD T175 C (rs4880) 
TT 11 16 38 38 0.002 0.32 (0.15-0.67) 0.47 (0.27-0.82) 
TC 20 29 60 60 
<0.0001 
0.30 (0.20-0.47) 0.51 (0.40-0.65) 
CC 37 55 2 2 59 (13.3-256.7) 3.95 (2.88-5.41) 
Total 68 100 100 100       
 
 
SOD3 R213G (rs1799895)  
CC 18 26 53 53 0.0006 0.32 (0.16-0.62) 0.49 (0.32-0.77) 
CG 29 42 45 45 NS 
GG 21 32 2 2 <0.0001 21.9 (4.93-97.29) 2.82 (2.16-3.68) 
Total 68 100 100 100       
Table 8: Genotype frequency of antioxidant genes in SCA and control group. 
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Patients and controls 
Genotypes Patients Controls 
p value OR RR 
n % n % 
GSTP1 A105G (rs1695) 
AA 19 28 52 52 0.002 0.36 (0.19-0.69) 0.53 (0.34-0.82) 
AG 18 26 36 36 NS 
GG 31 46 12 12 <0,0001 6.14 (2.85-13.26) 2.44 (1.75-3.38) 
Total 68 100 100 100       
 
GSTP1 C114T (rs1138272) 
CC 22 36 77 77 <0,0001 0.14 (0.07-0.29) 0.33 (0.23-0.50) 
CT 20 30 23 23 NS 
TT 26 38 0 0 <0,0001 Infinity 3.4 (2.62-4.36) 
Total 68 100 100 100       
 
GSTT1del 
NOR 17 25 72 72 
<0.0001 
0.13 (0.06-0.26) 0.30 (0.19-0.47) 
NULL 51 75 28 28 7.71 (3.83-15.56) 3.38 (2.14-5.34) 
Total 68 100 100 100      
 
GSTM1del 
NOR 65 96 99 99 NS 
NULL 3 4 1 1 
Total 68 100 100 100 
Table 9: Genotype frequency of detoxify genes in SCA and control group. 
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Graphic 4: Genotype frequency of detoxify genes in SCA and control group. 
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3.4. Patient’s polymorphisms stratified by: 
3.4.1. Gender 
 
The distribution of SCA subjects by gender shows no significant differences 
between men and women (Tables 10-13). 
 
 
Alleles 
Gender 
Male Female 
p OR RR 
n % n % 
MNSOD T175 C (rs4880) 
T 32 31 10 29 
NS 
C 70 69 24 71 
Total 102 100 34 100 
 
SOD3 R213G (rs1799895) 
C 45 44 20 59 
NS 
G 57 56 14 41 
Total 102 100 34 100 
 
Table 10: Allelic frequency of antioxidant genes by gender. 
 
 
 
Alleles Gender 
Male Female 
p OR RR 
n % n % 
GSTP1 A105G (rs1695) 
A 38 37 18 53 
NS 
G 64 63 16 47 
Total 102 100 34 100  
GSTP1 C114T (rs1138272) 
C 48 47 16 47 
NS 
T 54 53 18 53 
Total 102 100 34 100  
Table 11: Allelic frequency of detoxify genes by gender. 
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Gender 
Genotypes 
 
Male Female 
p OR RR 
n % n % 
MNSOD T175 C (rs4880) 
TT 9 18 2 12 
NS CT 14 27 6 35 
CC 28 55 9 53 
Total 51 100 17 100 
 
SOD3 R213G (rs1799895) 
CC 12 24 6 35 
NS CG 21 41 8 47 
GG 18 35 3 18 
Total 51 100 17 100 
 
Table 12: Genotype frequency of antioxidant genes by gender. 
 
 Gender 
Genotypes 
 
Male Female 
p OR RR 
n % n % 
GSTP1 A105G (rs1695) 
AA 12 24 7 41 
NS AG 14 27 4 24 
GG 25 49 6 35 
Total 51 100 17 100 
 
GSTP1 C114T (rs1138272) 
CC 16 31 6 35 
NS CT 16 31 4 24 
TT 19 38 7 41 
Total 51 100 17 100  
GSTT1del 
NOR 12 24 5 29 
NS 
NULL 39 76 12 71 
Total 51 100 17 100 
GSTM1del 
NOR 46 90 17 100 
NS 
NULL 5 10 0 0 
Total 51 100 17 100 
GSTM del 
NOR 7 14 2 12 
NS 
NULL 44 86 15 88 
Total 51 100 17 100  
Table 13: Genotype frequency of detoxify genes by gender. 
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3.4.2. Tumor localization 
 
Allele frequencies from polymorphisms of MNSOD, SOD3, GSTP, GSTT 
and GSTM genes in SCA subjects and controls are presented in Tables 6 and 7. 
The majority of genes did not present a significant difference between groups. Only 
GSTP1 alleles had significant difference between colon and rectum samples 
(p=0.03), being the mutated allele GSTP1 114T more prevalent among colon 
samples (63% vs 45%; p=0.03; OR: 2.11; CI 1.06 to 4.20) (Table 14).  
 
Allele 
Tumor localization 
Colon Rectal 
p OR RR 
n % n % 
MNSOD T175 C (rs4880) 
T 21 34 21 28 
NS 
C 41 66 53 72 
TOTAL  62 100 74 100 
 
 
SOD3 R213G (rs1799895) 
C 28 45 37 50 
NS 
G 34 55 37 50 
TOTAL 62 100 74 100 
 
 
GSTP1 A105G (rs1695) 
A 28 45 28 38 
NS 
G 34 55 46 62 
TOTAL 62 100 74 100 
 
 
GSTP1 C114T (rs1138272) 
C 23 37 41 55 
0.03 
0.48 (0.24-0.95) 0.72 (0.52-0.98) 
T 39 63 33 45 2.11 (1.06-4.20) 1.40 (1.02-1.91) 
TOTAL 62 100 74 100 
   
Table 14: Colon-rectal allele frequency in SCA patients 
 
 
In the same way, we found GSTP1 114TT mutated genotype associated 
with colon samples (52% vs 27%; p=0.003; OR: 2.88; CI: 1.41 to 5.89).  GSTT1 
null genotype were also prevalent among colon samples (87% vs 65%; p=0.003; 
OR: 3.66; CI 1.51 to 8.84) while the normal genotype were associated with rectum 
samples (Table 15; Graphic 5-6).  
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Genotypes 
Tumor localization 
Colon Rectal 
p OR RR 
n % n % 
MNSOD T175 C (rs4880) 
TT 10 16 12 16 
NS TC 22 36 18 24 
CC 30 48 44 60 
TOTAL 62 100 74 100 
 
 
SOD3 R213G (rs1799895) 
CC 16 26 20 27 
NS CG 24 39 34 46 
GG 22 35 20 27 
TOTAL  62 100 74 100 
 
 
GSTP1 A105G (rs1695) 
AA 18 29 20 27 
NS AG 20 32 16 22 
GG 24 39 38 51 
TOTAL  62 100 74 100 
 
 
GSTP1 C114T (rs1138272) 
CC 16 26 28 38 
NS 
CT 14 22 26 35 
TT 32 52 20 27 0.003 2.88 (1.41-5.89) 1.72 (1.20-2.47) 
TOTAL  62 100 74 100 
   
 
GSTT1 del 
NOR 8 13 26 35 
0.003 
0.27 (0.11-0.66) 0.62 (0.47-0.81) 
NULL 54 87 48 65 3.66 (1.51-8.84) 1.63 (1.23-2.15) 
TOTAL  62 100 74 100 
   
 
GSTM1 del 
NOR 32 52 40 54 
NS 
NULL 30 48 34 46 
TOTAL  62 100 74 100  
Table 15: Colon-rectal genotype frequency in SCA patients. 
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Graphic 5: Colon-rectal allelic frequency of GSTP gene in SCA patients (p=0.03). 
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Graphic 6: Colon-rectal genotype frequency of GSTP gene in SCA patients. 
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IV. Discussion 
SCA development is the result of a complex interaction of variables, 
including external factors such as exposure to environmental agents and dietary 
factors and internal factors. Sporadic colorectal cancer is influenced by the local 
colonic environment and the patient’s genetic background. It has been established 
that genotypes with low penetrance polymorphisms are related with detox 
metabolism and thus with risk of CRC. However, it is unknown their role on 
sporadic colorectal adenocarcinoma.  For this reason, the aim of this study was to 
determine whether these genetic polymorphisms influence the risk of SCA and 
their clinical/biological importance.  
Between the genes with antioxidant and detoxifying activity, superoxide 
dismutases (SOD) and glutathione-S-transferases (GST) genes are highly 
polymorphic and often contain numerous mutations, increasing the risk of the 
cancer development. Therefore, the study of MNSOD, SOD3, GSTP, GSTT and 
GSTM genotypes, involved in detox metabolism, is very important to clarify 
oxidative stress involvement in SCA development. These genes encode enzymes 
that can have their activity changed due mutations, on their variant alleles. These 
mutations are substitutions or deletions that encode different amino acids which 
have their enzymatic function altered or lost. These changes consequently lead to 
the alteration in the risk of malignant diseases, whether conferring a certain 
protection or increasing the risk of development of the disease due the 
accumulation of ROS.  
 
 Figure 19 A 
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In this view, we supposed that some antioxidant and detoxify 
polymorphisms would be involved in oxidative stress regulation (Figure 19 A-B). 
They may predispose to disease and particularly on SCA.  The strength of the 
biological impact will depend on heterozygosity or homozygosity of the variant 
allele. 
 
 
 
 
 
 
 
4.1. SCA subjects and controls 
4.1.1. Antioxidant genes 
 
Superoxide dismutases seem to have an important role on oxidative 
metabolism balance. They are the first line of enzymes responsible for antioxidant 
defense. SODs catalyze O2
- to H2O2 through reduction and re-oxidation of the 
metal on their active center. Loss of activity leads to ROS accumulation.  From the 
three main isoforms, SOD2 and SOD3 have been associated with carcinoma.23, 38, 
39, 43, 53, 56, 64, 75 The innumerous polymorphic variants of these genes confer 
different expression and active proprieties on antioxidant cellular defense.38, 39,  53-
56 Our results suggest that both SOD2 and SOD3 influence SCA risk. 
 
Figure 19 A-B: ROS accumulation disturbs oxidative regulation. For our turn, this 
imbalance leads to cancer development. 
Adapted from: Graves DB. The emerging role of reactive oxygen and nitrogen species in 
redox biology and some implications for plasma applications to medicine and biology. J Phys 
D Appl Phys. 2015; 45: 263001 
 
Figure 19 B 
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 SOD2 gene 
 
Several researches suggest that MnSOD genes influence CRC risk. This 
hypothesis is corroborated with our results. We observed a high correlation in 
mutant C alleles (69% vs 32%; p<0.0001; OR:4.76; RR 2.52) and CC genotypes 
175CC (54% vs 2%; p<0.0001; OR: 58,5; CI 13,3 to 256,7) in SCA patients when 
compared with control group. This mutation encodes an Ala variant with higher 
activity than the Val variant, suggesting that Ala/Ala genotypes subjects may have 
higher SOD2 activity. MnSOD, found in mitochondria, regulates cellular redox 
homeostasis that is known to regulate proliferative and quiescent growth states. 
Few studies have also reported that SOD2 is upregulated during tumor 
progression in prostate, colon and lung.76 SOD2 overexpression appears to 
enhance invasiveness and migration of malignant cells.76 Therefore, this 
overproduction of SOD2 increases the levels of H2O2 increasing cancer risk.  
Other authors observed an increased expression and activity of SOD isoenzymes 
in various types of tumors, implying MnSOD in tumors progression, 
aggressiveness and metastatic potential.66, 67, 72 However, there are still some 
differences between studies. The different clinical stages of the tumors studied 
could justify this inconsistences.66 
Furthermore, we can also observe that T allele, with normal activity levels, 
seems to have a protective effect on SCA. While C allele, over activated protein, 
increases the SCA risk. 
 
 SOD3 gene 
 
SOD3 is an extracellular enzyme highly expressed in plasma, blood 
vessels, heart, lungs, kidney, placenta and extracellular fluids. Like SOD2, it is a 
protective molecule that catalyzes the conversion of superoxide anions into 
hydrogen peroxide and oxygen. SOD3 binds to extracellular matrix protecting from 
oxidative fragmentation. It was observed that non-neoplastic tissue has more 
SOD3 expression than neoplastic tissue which supports the role of SOD3 in 
tumorigenesis. However, there is not much knowledge about EC-SOD in human 
tumors.77, 81, 82 SOD3 variant is known to reduce the binding capacity of SOD3. So 
transcript levels of SOD3 should differ between tumor and non-neoplastic tissues. 
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According to this, we observed a prevalence of SOD3 213G mutated allele 
(p<0.0001; 52% vs 25%; OR: 3.37; RR: 1.97) and SOD3 213GG mutated 
genotype (31% vs 2%; p<0.0001; OR: 21.89; CI 4.93 to 97.29). We can see that C 
allele is dominant, thus G allele has significance only when found in homozygous. 
It is expected that anchoring/binding to the extracellular matrix is compromised. 
Thus, like we saw, SOD3 is diminished in tumor tissue samples. Consequently, 
SOD3 would be free on plasma leaving matrix prone to fragmentation and DNA 
damage by ROS.  On the other hand, this fragmentation drives to an immune 
response via inflammatory cell migration.23, 31, 78, 79, 82, 86 We also observed that 2% 
of our group control had SOD3 R213G polymorphism which is according with the 
2-3% described on literature. Also, we can observe that C allele, with binding 
capacity to extracellular matrix, seems to have a protective effect on SCA. While G 
allele, without anchoring capacity, increases the SCA risk 
 
4.1.2. Detoxify genes 
 
Glutathione S-transferase (GST) is a super family of Phase II detoxification 
enzymes involved in the detoxification of xenobiotic compounds. They are 
responsible for glutathione (GSH)  conjugation to a wide variety of endogenous 
and exogenous electrophilic compounds formed during oxidative stress, such as, 
from lipid peroxidation.88-103 Electrophiles inactivation facilitates their excretion into 
urine or bile.88, 89 GST activities may be reduced in colonic mucosa affected by 
chronic inflammatory conditions.105 The lack of function of these enzymes has 
been correlated with a higher risk of cancer.  
Glutathione S-transferases are high polymorphic among ethnicities. The 
mammalian cytosolic family of GSTs is dividing into seven classes. From those 
classes pi, theta and mu have been identified in the human colon; when, the pi 
class predominates.105, 110, 111 SNPs in those isoforms change its enzyme catalytic 
activity which seems to denote impaired ability to detoxify carcinogens, conferring 
an increased cancer risk.90, 110, 112  
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 GSTP gene 
 
The GSTP1 genotype is overexpressed in a wide variety of tumors including 
ovarian, bladder, testicular, lung, breast, colon, pancreas, larynx and lymphoma.94, 
95, 97, 105, 110 We search for two genetic polymorphisms in GSTP1: Ile105Val and 
Ala114Val. GST expression and/or activity are lost in some individuals with those 
allelic variations. This change GSTP1 catalytic activity but no it’s binding affinity to 
glutathione.90, 110 A reduction of enzyme activity is followed by an increase of 
cellular oxidative stress which allows the human colon cancer cell survival and 
proliferation.94, 102, 110 However, the association between the Glutathione S 
transferase-P1 (GSTP1) Ile105Val polymorphism and colorectal cancer (CRC) 
susceptibility are still inconsistent between studies.102, 110, 113 
In our study, we notice that GSTP1 105G mutated allele (P<0.0001; 59% vs 
30%; OR: 3.33; RR:2) and GSTP1 105GG mutated genotype (46% vs 12%; 
p<0.0001; OR: 6.14; CI 2,85 to 13,26) were frequent among SCA subjects. We 
can see that A allele is dominant, thus G allele has only significance when found in 
homozygous. GSTP1 105Val polymorphism has a catalytic activity reduction and 
thus a diminished detoxification capacity in individuals with G mutated allele when 
compared with wild-type.97,112 Thus, we can presume that A allele, with normal 
activity levels, seems to have a protective effect on SCA. While G allele, with lower 
activity, increases the SCA risk. 
In the same way, GSTP1 114T (p<0.0001; 53% vs 12%; OR: 8.66; RR 
2.85) mutant allele and GSTP1 114TT (38% vs 0%; p<0.0001; OR: Infinity) 
mutated genotype were widespread in SCA subjects. Mutated T allele is 
associated with SCA risk and mutated TT genotype has a great association with 
this disease. In SCA we had 38% homozygous mutated polymorphisms whereas 
in our group control there was none. Therefore, we can presume that GSTP1 
Val114 polymorphism is associated with colorectal cancer susceptibility.  Also, C 
allele confers protective effect to SCA while T allele increases the risk.102, 110 
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 GSTT gene 
 
GSTT1 has a functional and a non-functional allele. Homozygosity for the 
nonfunctional allele of GSTT1 is the null phenotype and exhibits an absence of 
catalytic activity. In our study, we observed that this polymorphism was prevalent 
in Portuguese population. However, this association is not consistent between all 
studies reported. Individuals homozygous for this deletion are thought to be at 
increased risk for malignancies (such as cancer, cardiovascular and respiratory 
diseases).94, 95, 99, 101-104, 106 Similar to our data in SCA, several studies also 
reported that GSTT1 polymorphism was significant for CRC risk in 
Caucasians.95,101 Going into this, we observed a prevalence GSTT1 null (75% vs 
28%; p<0.0001; OR: 7.71; CI 3.83 to 15.56) genotype between SCA samples. 
Then, we can believe that subjects who carry GSTT1 null polymorphism have an 
increased SCA risk. Whereas, those who have GSTT1 functional genotype seems 
to have a lower SCA risk development.  
 
 GSTM gene 
 
Loss of GSTM enzyme function is described to a homozygous deletion of 
this gene resulting in the GSTM1 null allele. Data have suggested that this 
polymorphism is associated with an increased risk of CRC, especially in the 
Caucasian population.88, 89, 94-96, 99, 103-105,108 However, this research GSTM1 del 
mutated genotype was not statistical significance between SCA patients and 
control group. Thus, we did not find a correlation of this polymorphism with SCA 
risk. There are some topics that can justify these findings. If in one way, GSTM1 
have a low expression level in colon/rectum tissue (Figure 20), when compared 
with the other GSTs studied (Figure 21 and 22); in another way, GST are high 
polymorphic among ethnicities and we have not previous background of our 
population. Nevertheless, GSTM1 null polymorphism has no association with SCA 
risk among our subjects. 
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4.2. Gender 
 
This cancer affects aged people in both   sexes. As well other studies, there 
was no relation between any of the polymorphic variants and gender. We have no 
significant differences according to genotype distributions in patients. In our study, 
these results can be possibly explained by differences between sample genders 
distribution, since the majority of our samples are males (75% vs 25%). 
Nonetheless, it seems that most of polymorphisms distribution had no real 
difference among genders. In fact most studies reported no gender differences 
between CRC patients.   
 
 
4.3. Distinction between colonic and rectal Adenocarcinomas 
 
Colon cells are characterized by a rapid turnover with high rates of DNA 
synthesis. Several studies have shown a link between oxidative stress and DNA 
damage. Rectal carcinomas show similar development mechanisms as in distal 
colon tumors (descending and sigmoid colon). Therefore, significant differences 
Figure 20: Protein expression of GSTM1 in different tissues. 
Adapted from: http://cdn.genecards.org/images/v4/protein-
expression/protein_expression_GSTM1.png 
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between rectal and colon carcinomas with respect to genetic features have been 
reported. 
SCA subjects in this study were stratified according to the place of primary 
tumor: colonic or rectal. Our results show that GSTP1 114T and GSTP1 114TT 
genotype have a significant difference between colon and rectum location on SCA 
patients. This difference could be explained by the GSTP1 high expression in 
colon which leads to a huge impact of these variants on this tissue when 
compared with rectum (Figure 21). Moreover, this polymorphism has been 
reported to have an important role in inflammatory process.116,117 It is also known 
that inflammation could lead to colon cancer development, since most of colonic 
mucosa inflammatory diseases are associated with CRC risk.118, 119,120,121 In this 
sense, GSTP1 114 mutation can influence colon inflammation progression and 
tumorigeneses process in colon. This association can explain the prevalence of 
this mutation in colon samples when compared with rectum. A previous study has 
also associated GSTP gene with liver tumorigenesis.116    
 
 
Also, GSTT1 null variant reveals significant differences in primer tumor 
location. Our results show that GSTT1 null genotype has a higher prevalence in 
colon samples (87% vs. 64%). Like GSTP1 114T, this polymorphism has been 
Figure 21: Protein expression of GSTP1 in different tissues. 
Adapted from: http://cdn.genecards.org/images/v4/proteinexpression/protein_expression_GSTP1.png 
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reported to have an important role in inflammatory process control in colon 
tissue.121,122 GSTT1 null genotype promotes colon inflammation progression and 
tumorigenesis process and both processes are involved in colon cancer 
development. These mechanisms can explain the prevalence of this mutation in 
colon samples when compared with rectum (Figure 22). 
 
 
 
 
 
 
 
 
 
Figure 22: Protein expression of GSTT1 in different tissues. 
Adapted from: http://cdn.genecards.org/images/v4/protein-
expression/protein_expression_GSTT1.png 
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V. Conclusion 
 
CRC is known as a multifactorial disease. Some diet and social habits, such 
as alcohol and smoking behaviors, represent a higher risk to CRC.  However, the 
genetic influence is not fully understood.  There have been reported that oxidative 
stress is involved in CRC development. Antioxidant and detoxify enzymes, namely 
SOD and GST, regulates ROS toxicity cellular levels and are crucial to this process. 
Moreover, polymorphic variants of those enzymes could lead to a redox hemostasis 
imbalance, particularly in colon and rectal tissues. In our work, we found that 
MNSOD, SOD3, GSTP1 and GSTT1 common polymorphisms were associated with 
increased SCA risk in Portuguese population. In normal conditions, they belong to a 
defense mechanism that regulates ROS levels. However, MNSOD, SOD3, GSTP1 
and GSTT genes polymorphisms encodes dysfunctional proteins. Therefore the 
defense mechanism will fail and ROS will accumulate, inducing an oxidative stress 
on colonic and rectal cells. 
There may be others several possible mechanisms underlying all 
association studies, such as the results from interaction of both environmental and 
genetic factors, which can be responsible for analysis default. The sample size of 
the present study may not be large enough to detect the small effect of low 
penetrance mutations. The combined effect of multiple genes/mutations can 
provide more reliable information for genetic contribution to risk of SCA. We 
cannot completely exclude the effects of the other conditions (i.e. weight, gender, 
diet type, etc.) and residual confounding attributable to the measurement error 
(namely, lack of assess to patient’s diet and habits). It is essential a large 
approach study with large sample size to confirm our outcomes. Still, the present 
study provides preliminary evidence that MnSOD T175C, SOD3 R213G, GSTP1 
A105G, GSTP1 C114T and GSTT1 null polymorphisms, may be involved in SCA 
risk and could be useful to clarify this multifactorial disorder.  
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